Research press release


Nature Medicine

Dual protection against tuberculosis



C Aagaardたちは、活性な結核菌にだけでなく潜伏状態の結核菌に対しても免疫応答を起こさせるタンパク質を組み合わせた、新しいワクチンを開発した。この新戦略ワクチンは、ワクチンのすべての成分タンパク質に対する免疫応答を促進する。このワクチンは、3種類の曝露前マウスモデルにおいて結核予防効果を示し、2種類の結核潜伏感染マウスモデルでは再活性化を抑制した。

A new vaccine that can fight tuberculosis in mice before and after exposure to the infectious agent is reported online this week in Nature Medicine.

Tuberculosis vaccines currently in clinical trials have been designed to protect people before they are exposed to Mycobacterium, the pathogen responsible for the disease. However, many people experience what is called ‘latent infection’ in which the pathogen is in a resting, susceptible of being reactivated. This latent state is not targeted by existing tuberculosis vaccines.

Claus Aagaard and his colleagues developed a vaccination strategy that combines proteins that trigger an immune response to the active, as well as to the latent Mycobacterium. Their vaccine promotes an immune response against all protein components of the vaccine. The team found that the vaccine also confers protection against Mycobacterium in three different preexposure mouse models and it controls reactivation in two mouse models of latent tuberculosis.

doi: 10.1038/nm.2285


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。